StockMacro
Company, fund or insider

Help

Menu

NeoGenomics

$14.82 +60% in 6 monthsMarket cap $1.9B

NEO on XNAS, Services, NeoGenomics, Inc., job postings

Measures activity, not value. Not investment advice.

Short bets reached 16.7M shares, 2.8 times a year earlier, while the shares rose 40% in a year.

  • GoodRevenue rose 11% to $787.8M over the last 12 months
  • BadStill a net loss of $32.3M over the last 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Industry
Services-testing laboratories (Services)
Employees
2,500
Website
neogenomics.com
Listed
Nasdaq, US
Last results
28 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $209.3M, net loss $7.5M.
Quarter to 31 Dec 2021: revenue $125.7M, net income -$41.8MQuarter to 31 Dec 2021: revenue $125.7M, net income -$41.8MQuarter to 31 Mar 2022: revenue $117.2M, net income -$49.4MQuarter to 31 Mar 2022: revenue $117.2M, net income -$49.4MQuarter to 30 Jun 2022: revenue $125.1M, net income -$35.3MQuarter to 30 Jun 2022: revenue $125.1M, net income -$35.3MQuarter to 30 Sep 2022: revenue $128.8M, net income -$36.9MQuarter to 30 Sep 2022: revenue $128.8M, net income -$36.9MQuarter to 31 Dec 2022: revenue $138.7M, net income -$22.7MQuarter to 31 Dec 2022: revenue $138.7M, net income -$22.7MQuarter to 31 Mar 2023: revenue $137.2M, net income -$30.8MQuarter to 31 Mar 2023: revenue $137.2M, net income -$30.8MQuarter to 30 Jun 2023: revenue $146.9M, net income -$24.3MQuarter to 30 Jun 2023: revenue $146.9M, net income -$24.3MQuarter to 30 Sep 2023: revenue $152.0M, net income -$18.5MQuarter to 30 Sep 2023: revenue $152.0M, net income -$18.5MQuarter to 31 Dec 2023: revenue $155.6M, net income -$14.3MQuarter to 31 Dec 2023: revenue $155.6M, net income -$14.3MQuarter to 31 Mar 2024: revenue $156.2M, net income -$27.1MQuarter to 31 Mar 2024: revenue $156.2M, net income -$27.1MQuarter to 30 Jun 2024: revenue $164.5M, net income -$18.6MQuarter to 30 Jun 2024: revenue $164.5M, net income -$18.6MQuarter to 30 Sep 2024: revenue $167.8M, net income -$17.7MQuarter to 30 Sep 2024: revenue $167.8M, net income -$17.7MQuarter to 31 Dec 2024: revenue $172.0M, net income -$15.3MQuarter to 31 Dec 2024: revenue $172.0M, net income -$15.3MQuarter to 31 Mar 2025: revenue $168.0M, net income -$25.9MQuarter to 31 Mar 2025: revenue $168.0M, net income -$25.9MQuarter to 30 Jun 2025: revenue $181.3M, net income -$45.1MQuarter to 30 Jun 2025: revenue $181.3M, net income -$45.1MQuarter to 30 Sep 2025: revenue $187.8M, net income -$27.1MQuarter to 30 Sep 2025: revenue $187.8M, net income -$27.1MQuarter to 31 Dec 2025: revenue $190.2M, net income -$9.9MQuarter to 31 Dec 2025: revenue $190.2M, net income -$9.9MQuarter to 31 Mar 2026: revenue $186.7M, net income -$17.1MQuarter to 31 Mar 2026: revenue $186.7M, net income -$17.1MQuarter to 30 Jun 2026: revenue $201.7M, net income $2.2MQuarter to 30 Jun 2026: revenue $201.7M, net income $2.2MQuarter to 30 Sep 2026: revenue $209.3M, net income -$7.5MQuarter to 30 Sep 2026: revenue $209.3M, net income -$7.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $209.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$209.3M-$7.5M
30 Jun 2026$201.7M$2.2M
31 Mar 2026$186.7M-$17.1M
31 Dec 2025$190.2M-$9.9M
30 Sep 2025$187.8M-$27.1M
30 Jun 2025$181.3M-$45.1M
31 Mar 2025$168.0M-$25.9M
31 Dec 2024$172.0M-$15.3M
30 Sep 2024$167.8M-$17.7M
30 Jun 2024$164.5M-$18.6M
31 Mar 2024$156.2M-$27.1M
31 Dec 2023$155.6M-$14.3M
30 Sep 2023$152.0M-$18.5M
30 Jun 2023$146.9M-$24.3M
31 Mar 2023$137.2M-$30.8M
31 Dec 2022$138.7M-$22.7M
30 Sep 2022$128.8M-$36.9M
30 Jun 2022$125.1M-$35.3M
31 Mar 2022$117.2M-$49.4M
31 Dec 2021$125.7M-$41.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $787.8M $709.2M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +11% +5.8%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$32.3M -$113.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 44.8% 43.5% 38.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -6.3% -17.0% 6.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -4.1% -16.0% 2.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -3.9% 8.7%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$28.6M -$17.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $139.3M $164.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $374.7M $341.5M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $235.4M $177.4M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.47 0.77
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.19
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 23.9
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.4 1.2
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.7 1.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.4 2.3

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
NeoGenomicsNEO (this company) $1.9Bloss2.4+11%-4.1%
UL SolutionsULS $14.7B28.64.6+6.1%16.1%
TIC SolutionsTIC $1.9Bloss0.86+73%-5.1%
Custom Truck One SourceCTOS $2.0B67.20.97+5.8%1.4%
Xenia Hotels & ResortsXHR $2.0B5201.8+4.2%0.3%
Western UnionWU $1.8B5.50.46-2.1%8.3%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+11%

$209.3M vs $187.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+42%

$11.8M vs $8.3M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+12%

294 13F filers vs 263

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

141.5M shares held by 13F filers (30 Sep 2026) of 129.4M outstanding (23 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

10%

13.1M shares sold short (30 Oct 2026) of 129.4M outstanding (23 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.7

13.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-7.6%

14.2M shares sold short in the report before, 13.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

50%

50% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

77

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$2.6M

the 12 months before: $2.5M

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.0×

9 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 16.7M, 2.8× a year earlier

Price $14.82 on 20 Nov 2026, +40% over 12 months (12-month range $7.19 to $19.91)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $717K in the last 12 months (the 12 months before: $498K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $209.3M in the latest quarter, +11% on a year earlier.
Capital spending per quarter. Capital spending $11.8M in the latest quarter, +42% on a year earlier.
Institutional holders (13F filers). 294 13F filers reported holding it in the latest 13F quarter, +24% on a year earlier.
Federal obligations. Federal obligations: $1.9M published in the last 12 months, +4.2% on the 12 months before.
Lobbying spend. Lobbying spend: $0 published in the last 12 months, -100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Oct 2026Sharp changeShort interest spike: short interest spike, 14.2M vs usual 8.6M (2026-10-15); 2.2x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 14.2M vs usual 8.5M (2026-09-30); 2.4x the same period a year earlier
5 Oct 20268-K and other filingsDirector or officer change
29 Sep 2026Sharp changeShort interest spike: short interest spike, 16.7M vs usual 8.5M (2026-09-15); 2.8x the same period a year earlier
15 Sep 2026Sharp changeShort interest spike: short interest spike, 15.8M vs usual 8.4M (2026-08-31); 3.0x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 15.9M vs usual 8.4M (2026-08-14); 3.0x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 15.4M vs usual 8.4M (2026-07-31); 3.1x the same period a year earlier
11 Aug 20268-K and other filingsDirector or officer change
25 Jun 20268-K and other filingsDirector or officer change
22 May 20268-K and other filingsDirector or officer change
22 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Jan 20268-K and other filingsDirector or officer change
30 Dec 20258-K and other filingsDirector or officer change
30 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 54 vs usual 27.50 (2025-06-30); 2.2x the same period a year earlier
8 Aug 20258-K and other filingsDirector or officer change
24 Jun 20258-K and other filingsDirector or officer change
27 May 20258-K and other filingsDirector or officer change
8 May 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 262K)
18 Mar 20258-K and other filingsDirector or officer change
22 Jan 2025Lobbying filinglobbying engagement terminated (in-house)
15 Jan 20258-K and other filingsDirector or officer change
10 Jan 20258-K and other filingsDirector or officer change
5 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Apr 20248-K and other filingsDirector or officer change
23 Feb 20248-K and other filingsDirector or officer change
23 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Nov 2023Sharp changeFirst federal award: first federal award: NEOGENOMICS LABORATORIES, INC.: new Department of Veterans Affairs contract 36C25724N0100 ($2,787,350)
29 Jun 20238-K and other filingsDirector or officer change
17 May 20238-K and other filingsDirector or officer change
17 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Apr 2023Lobbying filinglobbying engagement terminated (CASSIDY & ASSOCIATES, INC.)
23 Jan 20238-K and other filingsDirector or officer change
22 Jan 2023Sharp changeLobbying on a new issue: lobbying on a new issue: BUD (2022-12-31)
6 Dec 20228-K and other filingsDirector or officer change
18 Nov 20228-K and other filingsDirector or officer change
7 Nov 20228-K and other filingsDirector or officer change
20 Oct 20228-K and other filingsDirector or officer change
12 Aug 20228-K and other filingsDirector or officer change
21 Jul 20228-K and other filingsDirector or officer change
11 May 20228-K and other filingsDirector or officer change
6 May 20228-K and other filingsDirector or officer change
25 Apr 20228-K and other filingsDirector or officer change
28 Mar 20228-K and other filingsDirector or officer change
9 Mar 20228-K and other filingsDirector or officer change
19 Jan 20228-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Nov 2021: -$4.6M published
Month from 1 Dec 2021: $456K published
Month from 1 Mar 2022: -$59K published
Month from 1 Nov 2023: -$49K published
Month from 1 Feb 2024: -$39K published
Month from 1 Mar 2024: -$98K published
Month from 1 May 2024: -$17K published
Month from 1 Aug 2024: -$17K published
Month from 1 Nov 2024: -$79K published
Month from 1 May 2025: $585K published
Month from 1 Aug 2025: $212K published
Month from 1 Oct 2025: -$49K published
Month from 1 Nov 2025: -$251K published
Month from 1 Jan 2026: -$277K published
Month from 1 Jun 2026: -$119K published
Month from 1 Aug 2026: -$321K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $125.7M, -0.2% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $117.2M, +1.4% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $125.1M, +2.8% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $128.8M, +6.1% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $138.7M, +10% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $137.2M, +17% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $146.9M, +17% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $152.0M, +18% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $155.6M, +12% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $156.2M, +14% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $164.5M, +12% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $167.8M, +10% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $172.0M, +11% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $168.0M, +7.5% on a year earlier; public on 30 Apr 2025
Quarter ended 30 Jun 2025: $181.3M, +10% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $187.8M, +12% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $190.2M, +11% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $186.7M, +11% on a year earlier; public on 29 Apr 2026
Quarter ended 30 Jun 2026: $201.7M, +11% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $209.3M, +11% on a year earlier; public on 29 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $12.0M, +4.2% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $8.2M, -48% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $10.3M, -52% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $7.8M, -48% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $4.5M, -62% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $9.9M, +21% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $7.5M, -27% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $4.3M, -46% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $7.1M, +56% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $5.6M, -44% on a year earlier; public on 1 May 2024
Quarter ended 30 Jun 2024: $13.1M, +75% on a year earlier; public on 31 Jul 2024
Quarter ended 30 Sep 2024: $10.8M, +153% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $11.6M, +64% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $4.5M, -19% on a year earlier; public on 30 Apr 2025
Quarter ended 30 Jun 2025: $6.3M, -52% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $8.3M, -23% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $7.9M, -32% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $5.0M, +11% on a year earlier; public on 29 Apr 2026
Quarter ended 30 Jun 2026: $8.2M, +30% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $11.8M, +42% on a year earlier; public on 29 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 281; public on 14 Feb 2022
31 Mar 2022 report: 264; public on 16 May 2022
30 Jun 2022 report: 228; public on 15 Aug 2022
30 Sep 2022 report: 218; public on 14 Nov 2022
31 Dec 2022 report: 223; public on 14 Feb 2023
31 Mar 2023 report: 241; public on 15 May 2023
30 Jun 2023 report: 239; public on 14 Aug 2023
30 Sep 2023 report: 254; public on 14 Nov 2023
31 Dec 2023 report: 264; public on 14 Feb 2024
31 Mar 2024 report: 246; public on 15 May 2024
30 Jun 2024 report: 242; public on 14 Aug 2024
30 Sep 2024 report: 256; public on 14 Nov 2024
31 Dec 2024 report: 248; public on 14 Feb 2025
31 Mar 2025 report: 247; public on 15 May 2025
30 Jun 2025 report: 264; public on 14 Aug 2025
30 Sep 2025 report: 237; public on 14 Nov 2025
31 Dec 2025 report: 250; public on 17 Feb 2026
31 Mar 2026 report: 248; public on 15 May 2026
30 Jun 2026 report: 263; public on 14 Aug 2026
30 Sep 2026 report: 294; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2023: $2.8M published
Month from 1 Dec 2023: $203K published
Month from 1 Jan 2024: $335K published
Month from 1 Feb 2024: -$47K published
Month from 1 Mar 2024: $975K published
Month from 1 Apr 2024: -$2.5M published
Month from 1 May 2024: $260K published
Month from 1 Jun 2024: -$125K published
Month from 1 Jul 2024: $108K published
Month from 1 Aug 2024: -$52K published
Month from 1 Sep 2024: $432K published
Month from 1 Oct 2024: $3.2M published
Month from 1 Nov 2024: $326K published
Month from 1 Dec 2024: $331K published
Month from 1 Mar 2025: $500K published
Month from 1 Apr 2025: -$2.0M published
Month from 1 May 2025: $59K published
Month from 1 Jun 2025: -$182K published
Month from 1 Jul 2025: -$131K published
Month from 1 Oct 2025: $3.3M published
Month from 1 Nov 2025: -$70K published
Month from 1 Dec 2025: -$31K published
Month from 1 Feb 2026: $52K published
Month from 1 Mar 2026: -$5K published
Month from 1 Apr 2026: $644K published
Month from 1 May 2026: $402K published
Month from 1 Jun 2026: -$1.5M published
Month from 1 Jul 2026: -$76K published
Month from 1 Sep 2026: -$111K published
Month from 1 Oct 2026: $2.8M published
Month from 1 Nov 2026: -$277K published
Lobbying spend
Quarter from 1 Jan 2022: $40K published
Quarter from 1 Apr 2022: $60K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $60K published
Quarter from 1 Jan 2023: $60K published
Quarter from 1 Apr 2023: $60K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Jul 2024: $40K published
Quarter from 1 Oct 2024: $40K published
Quarter from 1 Jan 2025: $40K published

What is unusual now

  • Made public in the last 90 days: it had 16.7M shares sold short in the 15 Sep 2026 report, 2.8× the same report last year; it also had 15.9M shares sold short in the 14 Aug 2026 report, 3.0× the same report last year. 5 sharp changes in all.
  • Short interest spike: had 16.7M shares sold short in the 15 Sep 2026 report, 2.8× the same report last year Public on 25 Sep 2026.
  • Insider net buying (open market): Insiders sold a net $717K in the last 12 months (the 12 months before: $498K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 6 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
6 Aug 2026Greg D AunanChief Accounting OfficerSell20,000$16.07$321KForm 4
17 Jun 2026Lynn A. TetraultDirectorSellplanned in advance (10b5-1)5,307$11.10$59KForm 4
11 Jun 2026Lynn A. TetraultDirectorSellplanned in advance (10b5-1)5,307$11.29$60KForm 4
21 Jan 2026Warren StonePres & Chief Operating OfficerSellplanned in advance (10b5-1)22,128$12.50$277KForm 4
28 Nov 2025Alicia C OlivoEVP, GC & Business DevelopmentSellplanned in advance (10b5-1); after exercising options20,916$12.00$251KForm 4
20 Oct 2025Alicia C OlivoEVP, GC & Business DevelopmentSellplanned in advance (10b5-1)4,918$10.00$49KForm 4
6 Aug 2025Jeffrey Scott ShermanChief Financial OfficerBuy20,000$5.62$112KForm 4
6 Aug 2025Anthony P. ZookChief Executive OfficerBuy17,900$5.58$100KForm 4

294 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 59 opened a position, 28 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.20.1M15.5%$368.9M-777K-3.7%
First Light Asset Management, LLC8.5M6.54%$155.3M-3.8M-31%
Greenhouse Funds LLLP8.4M6.49%$154.1M-179K-2.1%
Vanguard Portfolio Management LLC7.8M6.02%$143.0M-272K-3.4%
First Trust Advisors LP7.4M5.74%$136.3M-2.7M-27%
Vanguard Capital Management LLC5.7M4.44%$105.5M-19K-0.3%
State Street Corp5.3M4.13%$98.2M-17K-0.3%
Nomura Asset Management International Inc.4.7M3.63%$86.1M-346K-6.9%
Geode Capital Management, LLC3.4M2.64%$62.7M-12K-0.3%
Braidwell LP3.3M2.59%$61.5M-1.6M-32%

Federal contracts

All 4 federal contracts

1 new award in 12 months, $2.8M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
19 Oct 2026Department of Veterans Affairs$2.8MSTX SPECIALIZED REFERENCE LABORATORY TESTINGUSAspending
10 Oct 2025Department of Veterans Affairs$2.8MSTX SPECIALIZED REFERENCE LABORATORY TESTINGUSAspending
8 Oct 2024Department of Veterans Affairs$2.8MSTX SPECIALIZED REFERENCE LABORATORY TESTINGUSAspending
13 Nov 2023Department of Veterans Affairs$2.8MSTX SPECIALIZED REFERENCE LABORATORY TESTINGUSAspending

Company events

All 79 company events

In 12 months: 6 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
5 Oct 2026Director or officer changeSame filing: changed its bylaws or fiscal year8-K
11 Aug 2026Director or officer change8-K
25 Jun 2026Director or officer change8-K
22 Jun 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
22 May 2026Director or officer changeSame filing: shareholder vote results8-K
12 Jan 2026Director or officer change8-K
30 Dec 2025Director or officer change8-K
8 Aug 2025Director or officer change8-K

77 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 9%, People & recruiting 6%, Finance & accounting 5%, Research & science 5%.

PostedJobLocation
21 Nov 2026or earlierVariant Scientist, Tues-SatResearch & scienceRemote, United States
21 Nov 2026or earlierTest Case Coordinator for Oncology Diagnostic LaboratoryOperations & administrationFt Myers, Florida
21 Nov 2026or earlierTerritory Business Manager- South GA/JacksonvilleRemote, United States
21 Nov 2026or earlierTerritory Business Manager- Salt Lake City, UTRemote, United States
21 Nov 2026or earlierTerritory Business Manager - Oregon/IdahoRemote, United States
21 Nov 2026or earlierTemp Client Collections Specialist II2 Locations
21 Nov 2026or earlierTechnical Operations Scientist - Oncology Molecular DiagnosticsResearch & scienceAliso Viejo, California
21 Nov 2026or earlierSurgical PathologistFt Myers, Florida

Reported lobbying spend: $40K in Q4 2024, $40K in Q3 2024. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2024EndedNeogenomics Laboratoriesits own lobbyistsNot statedFiling
27 Feb 2023EndedCassidy & Associates, Inc.for Neogenomics Laboratoriesissues regarding VA procurement; Military Construction and Veterans Affairs AppropriationsVET, BudgetFiling
31 Dec 2021EndedMr. Alan Mertzfor Neogenomics LaboratoriesVALID legislation on genetic testingHealth issuesFiling
15 Apr 2021NewCassidy & Associates, Inc.for Neogenomics LaboratoriesIssues regarding VA procurementVETFiling
20 Aug 2018NewNeogenomics Laboratoriesits own lobbyistsDiagnostic Innovation and Accountability Act (DIAA) Protecting Access to Medicare Act (PAMA)MEDFiling
1 Jun 2017NewMr. Alan Mertzfor Neogenomics LaboratoriesLegislation dealing with the regulation and reimbursement of clinical laboratories.Health issuesFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

10 Aug 2021confirmed

Confirmed across sources Filings + Financials and Lobbying

NeoGenomics (NEO): lobbying on a new issue, while it spent $21.3M on capital projects in the quarter ended 30 Jun 2021, 4.2× the same quarter last year. Two unrelated kinds of activity within 27 days.

  • Lobbying: Lobbying on a new issue, became public on 14 Jul 2021
  • Financials: Quarterly capital spending jump, became public on 10 Aug 2021
2019-06-30: $3.4M2019-09-30: $7.3M2019-12-31: $6.1M2020-03-31: $4.7M2020-06-30: $5.0M2020-09-30: $7.9M2020-12-31: $11.5M2021-03-31: $15.8M2021-06-30: $21.3M
The quarter ended 30 Jun 2021 against the 8 quarters before it. this quarterearliernormal: $6.7M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 14 Jul 2021

NeoGenomics lobbying on a new issue.

New
['VET']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12774392

Financials: Quarterly capital spending jump became public on 10 Aug 2021

NeoGenomics spent $21.3M on capital projects in the quarter ended 30 Jun 2021, 4.2× the same quarter last year.

This period
$21.3M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$6.7M
Typical spread (median absolute deviation)
$1.8M
How far from its usual level
+5.4
Same quarter last year
$5.0M
History used
3,926 days
2019-06-30: $3.4M2019-09-30: $7.3M2019-12-31: $6.1M2020-03-31: $4.7M2020-06-30: $5.0M2020-09-30: $7.9M2020-12-31: $11.5M2021-03-31: $15.8M2021-06-30: $21.3M
the quarter ended 30 Jun 20218 earlier quartersnormal: $6.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 May 2019confirmed

Confirmed across sources Institutional holdings and Filings + Financials

NeoGenomics (NEO): reported revenue of $95.6M for the quarter ended 31 Mar 2019, 1.5× the same quarter last year, while it saw 63 13F filers open a new position in the quarter ended 31 Mar 2019, 4.5× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly revenue change, became public on 14 May 2019
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2019
2017-03-31: $61.7M2017-06-30: $66.1M2017-09-30: $63.1M2017-12-31: $67.8M2018-03-31: $63.4M2018-06-30: $67.7M2018-09-30: $69.1M2018-12-31: $76.5M2019-03-31: $95.6M
The quarter ended 31 Mar 2019 against the 8 quarters before it. this quarterearliernormal: $66.9M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 14 May 2019

NeoGenomics reported revenue of $95.6M for the quarter ended 31 Mar 2019, 1.5× the same quarter last year.

This period
$95.6M (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
$66.9M
Typical spread (median absolute deviation)
$2.8M
How far from its usual level
+4.3
Same quarter last year
$63.4M
History used
3,196 days
2017-03-31: $61.7M2017-06-30: $66.1M2017-09-30: $63.1M2017-12-31: $67.8M2018-03-31: $63.4M2018-06-30: $67.7M2018-09-30: $69.1M2018-12-31: $76.5M2019-03-31: $95.6M
the quarter ended 31 Mar 20198 earlier quartersnormal: $66.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 15 May 2019

NeoGenomics saw 63 13F filers open a new position in the quarter ended 31 Mar 2019, 4.5× the same quarter last year.

This period
63 (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
16.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+7.0
Same quarter last year
14
History used
2,008 days
2017-03-31: 182017-06-30: 152017-09-30: 152017-12-31: 72018-03-31: 142018-06-30: 232018-09-30: 292018-12-31: 502019-03-31: 63
the quarter ended 31 Mar 20198 earlier quartersnormal: 16.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 27 Oct 2026Short interest and volume change

    had 14.2M shares sold short in the 15 Oct 2026 report, 2.2× the same report last year.

    Same report last year: 6.5M; its normal report is 8.6M.

    See the evidence
    This period
    14.2M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    8.6M
    Typical spread (median absolute deviation)
    815K
    How far from its usual level
    +4.7
    Same report last year
    6.5M
    History used
    3,212 days
    2025-10-15: 6.5M2025-10-31: 7.2M2025-11-14: 8.4M2025-11-28: 9.1M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 10.0M2026-02-13: 8.9M2026-02-27: 8.5M2026-03-13: 8.4M2026-03-31: 7.6M2026-04-15: 7.9M2026-04-30: 9.5M2026-05-15: 8.6M2026-05-29: 8.5M2026-06-15: 8.5M2026-06-30: 11.6M2026-07-15: 13.8M2026-07-31: 15.4M2026-08-14: 15.9M2026-08-31: 15.8M2026-09-15: 16.7M2026-09-30: 14.2M2026-10-15: 14.2M
    the 15 Oct 2026 report24 earlier reportsnormal: 8.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 25 Oct 2026Government contracts record

    NEOGENOMICS LABORATORIES, INC.: new Department of Veterans Affairs contract 36C25727N0090 ($2.8M) (dated 19 Oct 2026)

  3. 10 Oct 2026Short interest and volume change

    had 14.2M shares sold short in the 30 Sep 2026 report, 2.4× the same report last year.

    Same report last year: 5.9M; its normal report is 8.5M.

    See the evidence
    This period
    14.2M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    8.5M
    Typical spread (median absolute deviation)
    730K
    How far from its usual level
    +5.2
    Same report last year
    5.9M
    History used
    3,197 days
    2025-09-30: 5.9M2025-10-15: 6.5M2025-10-31: 7.2M2025-11-14: 8.4M2025-11-28: 9.1M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 10.0M2026-02-13: 8.9M2026-02-27: 8.5M2026-03-13: 8.4M2026-03-31: 7.6M2026-04-15: 7.9M2026-04-30: 9.5M2026-05-15: 8.6M2026-05-29: 8.5M2026-06-15: 8.5M2026-06-30: 11.6M2026-07-15: 13.8M2026-07-31: 15.4M2026-08-14: 15.9M2026-08-31: 15.8M2026-09-15: 16.7M2026-09-30: 14.2M
    the 30 Sep 2026 report24 earlier reportsnormal: 8.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 5 Oct 2026Filings record

    Director or officer change

  5. 25 Sep 2026Short interest and volume change

    had 16.7M shares sold short in the 15 Sep 2026 report, 2.8× the same report last year.

    Same report last year: 5.9M; its normal report is 8.5M.

    See the evidence
    This period
    16.7M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    8.5M
    Typical spread (median absolute deviation)
    721K
    How far from its usual level
    +7.7
    Same report last year
    5.9M
    History used
    3,182 days
    2025-09-15: 5.9M2025-09-30: 5.9M2025-10-15: 6.5M2025-10-31: 7.2M2025-11-14: 8.4M2025-11-28: 9.1M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 10.0M2026-02-13: 8.9M2026-02-27: 8.5M2026-03-13: 8.4M2026-03-31: 7.6M2026-04-15: 7.9M2026-04-30: 9.5M2026-05-15: 8.6M2026-05-29: 8.5M2026-06-15: 8.5M2026-06-30: 11.6M2026-07-15: 13.8M2026-07-31: 15.4M2026-08-14: 15.9M2026-08-31: 15.8M2026-09-15: 16.7M
    the 15 Sep 2026 report24 earlier reportsnormal: 8.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 11 Sep 2026Short interest and volume change

    had 15.8M shares sold short in the 31 Aug 2026 report, 3.0× the same report last year.

    Same report last year: 5.2M; its normal report is 8.4M.

    See the evidence
    This period
    15.8M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    721K
    How far from its usual level
    +6.9
    Same report last year
    5.2M
    History used
    3,167 days
    2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 5.9M2025-10-15: 6.5M2025-10-31: 7.2M2025-11-14: 8.4M2025-11-28: 9.1M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 10.0M2026-02-13: 8.9M2026-02-27: 8.5M2026-03-13: 8.4M2026-03-31: 7.6M2026-04-15: 7.9M2026-04-30: 9.5M2026-05-15: 8.6M2026-05-29: 8.5M2026-06-15: 8.5M2026-06-30: 11.6M2026-07-15: 13.8M2026-07-31: 15.4M2026-08-14: 15.9M2026-08-31: 15.8M
    the 31 Aug 2026 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 26 Aug 2026Short interest and volume change

    had 15.9M shares sold short in the 14 Aug 2026 report, 3.0× the same report last year.

    Same report last year: 5.4M; its normal report is 8.4M.

    See the evidence
    This period
    15.9M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    721K
    How far from its usual level
    +7.0
    Same report last year
    5.4M
    History used
    3,150 days
    2025-08-15: 5.4M2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 5.9M2025-10-15: 6.5M2025-10-31: 7.2M2025-11-14: 8.4M2025-11-28: 9.1M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 10.0M2026-02-13: 8.9M2026-02-27: 8.5M2026-03-13: 8.4M2026-03-31: 7.6M2026-04-15: 7.9M2026-04-30: 9.5M2026-05-15: 8.6M2026-05-29: 8.5M2026-06-15: 8.5M2026-06-30: 11.6M2026-07-15: 13.8M2026-07-31: 15.4M2026-08-14: 15.9M
    the 14 Aug 2026 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 12 Aug 2026Short interest and volume change

    had 15.4M shares sold short in the 31 Jul 2026 report, 3.1× the same report last year.

    Same report last year: 5.0M; its normal report is 8.4M.

    See the evidence
    This period
    15.4M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    721K
    How far from its usual level
    +6.6
    Same report last year
    5.0M
    History used
    3,136 days
    2025-07-31: 5.0M2025-08-15: 5.4M2025-08-29: 5.2M2025-09-15: 5.9M2025-09-30: 5.9M2025-10-15: 6.5M2025-10-31: 7.2M2025-11-14: 8.4M2025-11-28: 9.1M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 10.0M2026-02-13: 8.9M2026-02-27: 8.5M2026-03-13: 8.4M2026-03-31: 7.6M2026-04-15: 7.9M2026-04-30: 9.5M2026-05-15: 8.6M2026-05-29: 8.5M2026-06-15: 8.5M2026-06-30: 11.6M2026-07-15: 13.8M2026-07-31: 15.4M
    the 31 Jul 2026 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 11 Aug 2026Filings record

    Director or officer change

  10. 25 Jun 2026Filings record

    Director or officer change

  11. 22 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 22 May 2026Filings record

    Director or officer change

  13. 12 Jan 2026Filings record

    Director or officer change

  14. 30 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 30 Dec 2025Filings record

    Director or officer change

  16. 16 Oct 2025Government contracts record

    NEOGENOMICS LABORATORIES, INC.: new Department of Veterans Affairs contract 36C25726N0072 ($2.8M) (dated 10 Oct 2025)

  17. 14 Aug 2025Institutional holdings change

    saw 54 13F filers open a new position in the quarter ended 30 Jun 2025, 2.2× the same quarter last year.

    Same quarter last year: 25; its normal quarter is 27.5.

    See the evidence
    This period
    54 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    27.5
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +4.0
    Same quarter last year
    25
    History used
    4,291 days
    2023-06-30: 322023-09-30: 322023-12-31: 232024-03-31: 242024-06-30: 252024-09-30: 302024-12-31: 152025-03-31: 402025-06-30: 54
    the quarter ended 30 Jun 20258 earlier quartersnormal: 27.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  18. 8 Aug 2025Filings record

    Director or officer change

  19. 7 Aug 2025Insiders record

    Sherman Jeffrey Scott (Chief Financial Officer) bought 20,000 shares of NEO ($112,400) (dated 6 Aug 2025)

  20. 7 Aug 2025Insiders record

    Zook Anthony P. (Chief Executive Officer) bought 17,900 shares of NEO ($99,882) (dated 6 Aug 2025)

  21. 24 Jun 2025Filings record

    Director or officer change

  22. 29 May 2025Insiders record

    Kelly Michael Aaron (director) bought 5,000 shares of NEO ($38,000) (dated 28 May 2025)

  23. 27 May 2025Filings record

    Director or officer change

  24. 14 May 2025Insiders record

    Stone Warren (Pres & Chief Operating Officer) bought 5,700 shares of NEO ($48,906) (dated 13 May 2025)

  25. 10 May 2025Insiders record

    TETRAULT LYNN A. (director) bought 7,000 shares of NEO ($56,980) (dated 9 May 2025)

  26. 10 May 2025Insiders record

    KANOVSKY STEPHEN M (director) bought 4,000 shares of NEO ($31,120) (dated 9 May 2025)

  27. 9 May 2025Insiders record

    Zook Anthony P. (Chief Executive Officer) bought 18,900 shares of NEO ($148,932) (dated 8 May 2025)

  28. 8 May 2025Insiders change

    had 3 insiders buy $262K of its shares on the open market within 30 days (3 filings).

    Who bought: Sherman Jeffrey Scott, Perez David Brian, Gunn Neil.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $262K
    Window
    8 Apr 2025 to 8 May 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  29. 8 May 2025Insiders record

    Gunn Neil (director) bought 4,510 shares of NEO ($35,000) (dated 7 May 2025)

  30. 8 May 2025Insiders record

    Perez David Brian (director) bought 10,000 shares of NEO ($76,300) (dated 7 May 2025)

  31. 7 May 2025Insiders record

    Sherman Jeffrey Scott (Chief Financial Officer) bought 20,000 shares of NEO ($150,200) (dated 6 May 2025)

  32. 18 Mar 2025Filings record

    Director or officer change

  33. 22 Jan 2025Lobbying record

    NEOGENOMICS LABORATORIES: lobbying engagement terminated (in-house) (dated 31 Dec 2024)

  34. 15 Jan 2025Filings record

    Director or officer change

  35. 10 Jan 2025Filings record

    Director or officer change

  36. 5 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 5 Nov 2024Filings record

    Director or officer change

  38. 14 Oct 2024Government contracts record

    NEOGENOMICS LABORATORIES, INC.: new Department of Veterans Affairs contract 36C25725N0072 ($2.8M) (dated 8 Oct 2024)

  39. 18 Apr 2024Filings record

    Director or officer change

  40. 23 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 121 entries; narrow the window or the kind of data to see older ones.

Not listed: 229 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001077183
Ticker
NEO
Domain
neogenomics.com
Hq location
FL|FORT MYERS|33912 (1 unverified)
Name
AMERICAN COMMUNICATIONS ENTERPRISES INC, Document, EX-21.1, Inivata Limited, a UK limited company and 5 more
Uei
TQR2U5AMPN76
Wikidata
Q48976818
Wikipedia
NeoGenomics
  • DOL H-1B labor condition applications and PERM certifications16 data points2 Feb 2026 to 24 Aug 2026
  • Federal lobbying disclosures (LDA)6 records, 83 data points1 Jun 2017 to 31 Dec 2024
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)198 records3 Feb 2016 to 28 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1142 data points31 Dec 2009 to 23 Oct 2026
  • SEC Form 4 insider transactions109 records, 364 data points4 Mar 2016 to 6 Aug 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards4 records, 186 data points13 Nov 2023 to 18 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026